ABT (NYSE) stock page - price, fundamentals, dividends - iOCharts

ABT

120.80
+2.55 (2.16%)
Abbott Laboratories (NYSE, USD)
Healthcare >
Medical Devices
Market cap
214.64B
Ent value
245.58B
Price/Sales
6.20
Price/Book
-
Div yield
1.49%
Div growth
8.45%
Growth years
8
FCF payout
54.21%
Trailing P/E
47.75
Forward P/E
26.03
PEG
4.14
EPS growth
12.40%
1 year return
19.82%
3 year return
24.10%
5 year return
22.92%
10 year return
16.92%
Last updated: 2021-07-23

STOCK INFORMATION

Stock chart
Loading...
Stock price data
All-time high128.23
1y analyst estimate125.81
Beta0.68
EPS (TTM)2.54
Dividend per share1.80
Ex-div date14 Jul 2021
Next earnings date22 Jul 2021
Downside potential
Loading...
Downside potential data
ABTS&P500
Current price drop from All-time high-5.79%-
Highest price drop-46.27%-56.47%
Date of highest drop23 Jul 20029 Mar 2009
Avg drop from high-11.28%-11.54%
Avg time to new high19 days13 days
Max time to new high1275 days1805 days

DIVIDENDS

Dividend yield - 5y
Loading...
Dividend yield data
Dividend per share1.80
Dividend yield1.49%
Payout frequencyQuarterly
Maximum yield2.82%
Average yield1.85%
Minimum yield1.29%
Discount to avg yield-24.14%
Upside potential-19.45%
Yield as % of max yield52.86%
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
Dividend yield1.49%
Current yield distribution90.87%
Yield at 100% (Min)1.29%
Yield at 90%1.50%
Yield at 80%1.55%
Yield at 50% (Median)1.74%
Yield at 20%2.17%
Yield at 10%2.43%
Yield at 0% (Max)2.82%
Dividend per share
Loading...
Dividend per share data
Years of growth8 years
CCC statusDividend Challenger
Dividend per share1.80
Payout frequencyQuarterly
Ex-div date14 Jul 2021
EPS (TTM)2.54
EPS (1y forward)4.64
EPS growth (5y)12.40%
EPS growth (5y forward)11.53%
Dividend growth
Loading...

Please create a free account or log in to access this chart

Dividend growth data
ABTS&P500
DGR MR25.00%7.68%
DGR TTM22.14%-2.66%
DGR 3 years10.75%5.82%
DGR 5 years8.45%6.23%
DGR 10 years5.76%9.64%
DGR 15 years7.04%6.71%
Time since last change announced225 days
EPS growth (5y)12.40%
EPS growth (5y forward)11.53%
Payout ratio
Loading...

Please create a free account or log in to access this chart

Payout ratio data
EPS coverageFCF coverage
TTM56.95%54.21%
Average--
Forward38.79%-

FINANCIALS

Per share
Loading...
Per share data
Current share count1.78B
EPS (TTM)2.54
FCF per share (TTM)2.67
Income statement
Loading...
Income statement data
Revenue (TTM)34.61B
Gross profit (TTM)19.61B
Operating income (TTM)5.36B
Net income (TTM)4.50B
EPS (TTM)2.54
EPS (1y forward)4.64
Margins
Loading...
Margins data
Gross margin (TTM)56.65%
Operating margin (TTM)15.48%
Profit margin (TTM)12.99%
Balance Sheet
Loading...

Please create a free account or log in to access this chart

Balance Sheet data
Cash8.05B
Net receivables8.06B
Total current assets21.82B
Goodwill23.38B
Intangible assets14.18B
Property, plant and equipment8.83B
Total assets72.78B
Accounts payable11.51B
Short/Current long term debt18.44B
Total current liabilities12.46B
Total liabilities39.00B
Shareholder's equity0.00
Net tangible assets5.04B
Cash flow
Loading...

Please create a free account or log in to access this chart

Cash flow data
Operating cash flow (TTM)7.90B
Capital expenditures (TTM)3.18B
Free cash flow (TTM)4.72B
Dividends paid (TTM)2.56B
Financial returns
Loading...

Please create a free account or log in to access this chart

Financial returns data
Return on Equity13.62%
Return on Assets6.20%
Return on Invested Capital8.69%
Cash Return on Invested Capital9.12%
COMPANY DETAILS
ABT (Abbott Laboratories) company logo
Marketcap
214.64B
Marketcap category
Large-cap
Description
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Employees
109000
SEC filings
CEO
Robert Ford
Country
USA
City
Abbott Park
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Loading...